Peptide Schedule
BAM-15Small moleculeNo amino acid sequence. Icon reflects category theme only.BAM-15
Benefits
About BAM-15
BAM-15 (N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a small-molecule mitochondrial uncoupler that has attracted significant attention in metabolic research circles. Although it is not a peptide, BAM-15 is frequently discussed alongside peptide-based metabolic agents because of its potent effects on energy expenditure and fat oxidation in preclinical models. Mitochondrial uncouplers work by dissipating the proton gradient across the inner mitochondrial membrane, forcing cells to burn more fuel to maintain their electrochemical potential. What makes BAM-15 stand out from older uncouplers like DNP (2,4-dinitrophenol) and FCCP is its selectivity: BAM-15 depolarizes mitochondrial membranes without affecting plasma membrane potential. This selectivity translates to substantially lower cytotoxicity at effective doses. In cell-based assays, BAM-15 can sustain maximal mitochondrial respiration rates without triggering apoptosis — something classical uncouplers cannot do safely. The landmark 2020 study published in Nature Communications demonstrated that mice fed a high-fat western diet supplemented with BAM-15 had significantly reduced body fat mass, improved insulin sensitivity across multiple tissue types, and decreased hepatic lipid accumulation — all without any reduction in food intake, lean body mass, or body temperature. Hyperinsulinemic-euglycemic clamp studies confirmed whole-body insulin sensitization. Importantly, hematological and biochemical markers of toxicity remained normal throughout the study. BAM-15 is orally bioavailable at approximately 67% in mice, with a Cmax of 8.2 micromolar and a half-life of 1.7 hours. It primarily accumulates in the liver and clears from tissues within four hours. The short half-life is a recognized limitation that researchers are working to address through formulation strategies and structural derivatives like SHM115. Beyond obesity, BAM-15 has shown preclinical activity in sepsis-associated kidney injury, acute myeloid leukemia, and Toxoplasma gondii infection, underscoring the broad therapeutic potential of targeted mitochondrial uncoupling.
Who Should Consider BAM-15
- Researchers studying mitochondrial uncoupling and metabolic disease
- Individuals interested in non-stimulant approaches to fat loss
- People exploring alternatives to classical uncouplers like DNP
- Those investigating adjuncts to diet and exercise for body composition
- Metabolic optimization enthusiasts seeking preclinical-stage compounds
How BAM-15 Works
BAM-15 is an anionic protonophore that targets the inner mitochondrial membrane. Under normal conditions, the electron transport chain pumps protons from the mitochondrial matrix into the intermembrane space, creating a proton motive force (PMF) that drives ATP synthase. BAM-15 short-circuits this process by carrying protons back across the inner membrane through a non-enzymatic pathway, dissipating the electrochemical gradient independently of ATP synthase. The aniline nitrogen in BAM-15's oxadiazolopyrazine scaffold acts as the acidic proton-shuttling moiety. On planar bilayer lipid membranes and in liposomes, BAM-15 induces proton conductance with potency comparable to the classical uncoupler CCCP. In isolated rat liver mitochondria, BAM-15 collapses membrane potential, accelerates respiration rate, and triggers calcium efflux. The key distinction from older uncouplers is membrane selectivity. BAM-15 depolarizes mitochondria at concentrations that leave the plasma membrane potential intact. This means cells increase their oxygen consumption and nutrient oxidation to restore the mitochondrial gradient, burning more calories in the process, without the widespread cellular toxicity that comes from plasma membrane disruption. To compensate for the dissipated PMF, cells must oxidize additional substrates — glucose and fatty acids — and shuttle more electrons through the transport chain, resulting in increased whole-body energy expenditure and fat oxidation.
What to Expect
Initial dosing phase. Due to the short 1.7-hour half-life, plasma levels do not accumulate significantly between doses. Some users report a subtle increase in warmth or metabolic rate within hours of dosing. No visible body composition changes expected.
Consistent daily dosing establishes a pattern of transient mitochondrial uncoupling. Increased energy expenditure may become noticeable during active dosing windows. No measurable fat loss expected yet in most individuals.
Based on mouse model data, fat mass reduction becomes measurable with sustained daily administration. Insulin sensitivity improvements were detectable by this timeframe in preclinical studies. Hepatic lipid levels may begin to decrease.
In the mouse obesity study, significant reductions in body fat mass and improved glycemic control were well established by this point. Body temperature and lean mass remained unchanged throughout. Effects are expected to reverse within days of discontinuation given the short half-life.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mg | Daily |
| Moderate | 10mg | Daily |
| Aggressive | 20mg | Daily |
Note: Oral small molecule — no reconstitution or injection required. BAM-15 is a mitochondrial protonophore uncoupler, not a peptide, but is included because it is widely discussed in peptide and metabolic optimization communities. CAS number 210302-17-3. Chemical formula C16H10F2N6O. Low water solubility aids mitochondrial membrane penetration. The short half-life (~1.7 hours) is a known limitation — split dosing or extended-release formulations may improve sustained exposure. All efficacy and safety data are from cell culture and rodent studies. No human clinical trials have been conducted.
How to Inject BAM-15
BAM-15 is taken orally as a capsule or dissolved in a carrier. In mouse studies, it was administered mixed into food at concentrations of 0.05% to 0.15% of diet weight, with 0.10% being the most studied dose. Human-equivalent dosing has not been established through clinical trials. Research community protocols typically range from 5-20 mg per day taken with food. Due to the short 1.7-hour half-life, splitting the daily dose into two or three administrations may provide more sustained plasma levels. BAM-15 has low water solubility, so it is typically formulated in capsules with lipophilic carriers or dissolved in DMSO for research use.
Cycling Protocol
No established human cycling protocol exists. In the primary mouse study, BAM-15 was administered continuously via diet for the study duration. An 8-week-on, 4-week-off schedule is a conservative extrapolation commonly discussed in research communities. The short half-life means pharmacological effects cease within hours of the last dose, so extended washout periods are likely unnecessary from a pharmacokinetic standpoint. Cycling rationale is based on general precaution rather than observed tolerance or tachyphylaxis.
Pharmacokinetics
Source: Axelrod et al. Nature Communications 2020 (PMID: 32409697) — oral PK in C57BL/6J mice
Loading the interactive decay curve.
Side Effects
BAM-15 has no published human clinical data, so all safety information comes from cell culture and rodent studies. In preclinical experiments, mice receiving BAM-15 intraperitoneally for more than 7 days showed no obvious clinical toxicity at any tested dose. Hematological and biochemical markers of toxicity remained within normal ranges. Body temperature was unaffected, which is a meaningful safety signal given that classical uncouplers like DNP can cause fatal hyperthermia. BAM-15 did not induce apoptosis at effective concentrations in cell-based assays. At high concentrations, slight inhibition of mitochondrial respiration has been observed, but this effect is substantially less than what occurs with FCCP. The short 1.7-hour half-life means any adverse effects would be expected to resolve within hours. Long-term safety profiles remain unknown. Because BAM-15 increases metabolic rate at the mitochondrial level, theoretical concerns include excessive energy depletion with overdose, though this has not been observed in published studies.
Contraindications
- Pregnancy or breastfeeding — no reproductive safety data available
- Known mitochondrial disorders (e.g., mitochondrial myopathy, MELAS) — uncoupling may worsen energy deficit
- Severe hepatic impairment — BAM-15 primarily accumulates in the liver
- History of hyperthermia or malignant hyperthermia susceptibility
- Active use of other mitochondrial uncouplers (DNP, FCCP) — additive uncoupling risk
- Caloric restriction below 1,200 kcal/day — increased energy expenditure may cause excessive energy deficit
- Children and adolescents — no safety data in developing organisms
Drug Interactions
- DNP and other mitochondrial uncouplers — additive uncoupling effect could cause dangerous energy depletion and hyperthermia
- Metformin — both compounds affect mitochondrial function; metformin inhibits Complex I while BAM-15 dissipates proton gradient; theoretical risk of excessive mitochondrial stress
- Insulin and sulfonylureas — BAM-15 improves insulin sensitivity, which could potentiate hypoglycemic effects
- Thyroid hormones (levothyroxine) — thyroid hormones naturally increase metabolic rate; additive thermogenic effect possible
- Beta-2 agonists (clenbuterol, albuterol) — combined metabolic stimulation may cause excessive energy expenditure
- Statins — some statins have mitochondrial effects; theoretical interaction with concurrent uncoupling, though not studied
Storage & Stability
Related Peptides
References
- Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice (Nature Communications 2020)PubMed 32409697
- BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control (EMBO Mol Med 2020)PubMed 32090499
- Protonophoric action of BAM15 on planar bilayers, liposomes, mitochondria, bacteria and neurons (Bioelectrochemistry 2021)PubMed 32971482
- BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases (Front Endocrinol 2023)PubMed 37900126
- BAM15 treats mouse sepsis and kidney injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophils (J Clin Invest 2023)PubMed 36757801
- Identification of a mitochondrial protonophore (BAM15) that is selective for mitochondria and reduces body fat in mice (Mol Metab 2014)PubMed 24944898